Elevance Health, Inc. (ELV) 股票分析

公司概述

Elevance Health, Inc. operates as a prominent health benefits company within the United States, managing operations across four distinct segments including Health Benefits, CarelonRx, Carelon Services, and Corporate & Other to serve individual and employer groups. The enterprise functions within the Healthcare sector and specifically the Healthcare Plans industry, positioning it as a key provider of health plans and essential services to the American population. This massive entity commands a substantial market capitalization of $69.93 billion while generating annual revenue that totals $199.13 billion, supported by a workforce of 96,129 employees. The sheer magnitude of its market cap and revenue figures indicates that Elevance Health holds a dominant position within the healthcare landscape, reflecting its extensive reach and significant economic footprint in the nation's health benefits market.

财务健康

The company reported a total revenue of $199.13 billion for the trailing twelve months, accompanied by a net income of $5.66 billion and an EBITDA of $9.04 billion. The substantial disparity between the $199.13 billion in revenue and the $5.66 billion in net income highlights a cost structure where operating expenses, including claims payments, administrative costs, and other overheads, consume a significant portion of top-line earnings before arriving at the bottom line. Free cash flow stands at $3.40 billion, which provides the company with the necessary financial flexibility to fund operational needs, service debt obligations, or pursue strategic initiatives without relying heavily on external financing. Profitability is further dissected by three key margins: a gross margin of 25.6%, an operating margin of 1.5%, and a profit margin of 2.8%, where the low operating and profit margins relative to the gross margin suggest high operational intensity and the critical importance of controlling administrative and medical cost trends. On the balance sheet, the company holds $36.12 billion in cash against $32.75 billion in debt, resulting in a debt-to-equity ratio of 74.39, which indicates a leveraged balance sheet structure where debt is substantial but partially offset by significant cash reserves. Liquidity is supported by a current ratio of 1.53, signaling that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable buffer. Efficiency and capital generation are measured by a return on equity of 13.2% and a return on assets of 4.4%, metrics that reveal the effectiveness of management in generating returns from shareholders' capital and utilizing the total asset base to drive profitability.

估值评估

Valuation metrics for Elevance Health show a trailing P/E ratio of 12.56 compared to a forward P/E of 10.76, implying that the market expects earnings growth that would justify a lower multiple in the future relative to current earnings. The price-to-book ratio is recorded at 1.59, indicating that the stock trades at a premium of 59% over its book value, which reflects investor confidence in the company's intangible assets and future earning potential beyond its tangible net worth. Alternative valuation measures include a price-to-sales ratio of 0.35 and an EV/EBITDA of 7.38, suggesting that the company is valued conservatively relative to its sales volume and enterprise earnings before interest, taxes, depreciation, and amortization. The stock has traded within a 52-week range bounded by a high of $458.75 and a low of $273.71, meaning the current price sits at a point that reflects recent market volatility within this established historical band. Additionally, the beta value of 0.50 indicates that the stock exhibits significantly lower price volatility relative to the broader market, moving at roughly half the magnitude of the market index during periods of fluctuation.

Growth & Income

Revenue growth is recorded at 9.5% year-over-year, while earnings growth is significantly higher at 36.3% year-over-year, implying that the company is successfully expanding its margins or benefiting from one-time gains that are outpacing top-line sales expansion. As a dividend payer, the company offers a dividend yield of 2.2% with a payout ratio of 27.1%, indicating that the dividend is highly sustainable given the low payout ratio which leaves ample earnings for reinvestment or to buffer against future downturns. The low payout ratio further suggests that the company retains a majority of its earnings to fuel internal growth initiatives, research, or debt reduction rather than maximizing immediate shareholder distributions. Overall, the growth and income profile presents a balance of steady revenue expansion, accelerating earnings performance, and a conservative, sustainable dividend policy that supports long-term shareholder value without aggressive payout pressure.